Phone: (650) 364-7016
info@cardiokinetix.com

PARACHUTE^TM Featured on CBS Early Show

 

 

 

 

PARACHUTE^TM Advantages

• Percutaneous Procedure
• Local Conscious Sedation

The PARACHUTE^TM Procedure

The PARACHUTE^TM procedure intends to address heart failure patients who have developed left-sided heart failure following a Myocardial Infarction (MI) heart attack. MI typically damages the heart muscle, due to lack of blood supply to the region during heart attack.

After MI many HF patients experience enlargement of their left ventricle causing a decrease in cardiac output resulting in heart failure symptoms such as shortness of breath.

CardioKinetix, Inc. has developed a percutaneous treatment for patients with left ventricular dilation after an anterior MI. The implantable device, called the PARACHUTE^TM is a partitioning membrane deployed within the compromised ventricle. The PARACHUTE^TM partitions the damaged muscle, isolating the non-functional muscle segment from the functional segment, and decreases the overall volume. Options for patients whose ventricle has enlarged are limited, with most on medical therapy and/or a cardiac resynchronization device that only benefits heart failure patients with a specific EKG pattern.

The PARACHUTE^TM procedure is performed in the cardiac catheterization lab or surgical suite, with the patient receiving local anesthesia. Under imaging guidance, the physician inserts the self-attaching PARACHUTE^TM device through the femoral artery, and deploys it into the apex of the left ventricle. The PARACHUTE^TM device partitions off the portion of the ventricle affected by the damaged myocardium, reducing the volume of the ventricle and increasing ejection fraction (a measure of the effectiveness of the ventricle).

The PARACHUTE^TM device, implanted by an Interventional Cardiologist, has demonstrated in trials that patients experience a significant decrease in heart failure symptoms up to 24 months and an increase in exercise capacity and quality of life up to 12 months; with few device related safety events. The trial also established that the device can be routinely implanted by interventional cardiologists under local anesthesia, with patients discharged in twenty-four hours.